Jin Medical International (ZJYL) Equity Average (2023 - 2025)
Jin Medical International (ZJYL) has disclosed Equity Average for 3 consecutive years, with $15.8 million as the latest value for Q3 2025.
- Quarterly Equity Average fell 40.01% to $15.8 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $15.8 million through Sep 2025, down 40.01% year-over-year, with the annual reading at $15.8 million for FY2025, 40.01% down from the prior year.
- Equity Average hit $15.8 million in Q3 2025 for Jin Medical International, down from $26.3 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $26.3 million in Q3 2024 to a low of $15.8 million in Q3 2025.
- Historically, Equity Average has averaged $20.5 million across 3 years, with a median of $19.6 million in 2023.
- Biggest five-year swings in Equity Average: skyrocketed 33.96% in 2024 and later tumbled 40.01% in 2025.
- Year by year, Equity Average stood at $19.6 million in 2023, then surged by 33.96% to $26.3 million in 2024, then crashed by 40.01% to $15.8 million in 2025.
- Business Quant data shows Equity Average for ZJYL at $15.8 million in Q3 2025, $26.3 million in Q3 2024, and $19.6 million in Q3 2023.